Disruptive gene therapy tech at heart of new eye disease company

31 October 2022
replay_big

A new gene therapy start-up, Eudora, has been launched by the Anglo-American genome writing company Replay.

Based in London and California, Replay is focused on “writing and delivering big DNA,” and has a distinctive approach to its corporate structure, aiming to separate work on its technology from the resulting therapeutic candidates.

The company has assembled a toolkit of what it hopes will be disruptive platform technologies, including a high payload capacity herpes simplex virus (HSV) platform, a hypoimmunogenic platform, and a genome writing platform.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology